Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Tiziano Barbui, Elisa Rumi et al.|Blood Cancer Journal|2018Cited by 38
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreTiziano Barbui, Alessandro M. Vannucchi, Arianna Ghirardi et al.|Blood Cancer Journal|2022Cited by 14
The Interaction between IPSS Score and JAK2 Mutation Identifies Patients at Different Vascular Risk in Primary MyelofibrosisTiziano Barbui, Björn Andréasson, Arianna Ghirardi et al.|Blood|2021Cited by 2